PRODUCT INFORMATION

BO-264

Item No. 36611

CAS Registry No.:	2408648-20-2
Formal Name:	N-[3-(4-methoxyphenyl)-5-isoxazolyl]-2-(4-morpholinyl)-4-pyrimidinamine
MF:	$C_{18}H_{19}N_5O_3$
FW:	353.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 252, 312 nm
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BO-264 is supplied as a solid. A stock solution may be made by dissolving the BO-264 in the solvent of choice, which should be purged with an inert gas. BO-264 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BO-264 in these solvents is approximately 1 and 10 mg/ml, respectively.

Description

BO-264 is a transforming acidic coiled-coil containing protein 3 (TACC3) inhibitor.[1] It binds to TACC3 in thermal shift and drug affinity responsive target stability (DARTS) assays and inhibits the growth of JIMT-1, HCC1954, MDA-MB-231, MDA-MB-436, and CAL-51 cancer cells (IC_{50}s = 0.19, 0.16, 0.12, 0.13, and 0.36 µM, respectively). BO-264 is cytotoxic to RT4 cells that endogenously express TACC3-FGFR3 fusion proteins (IC_{50} = 3.66 µM). It induces mitotic arrest, apoptosis, and aberrant spindle formation and reduces centrosomal localization of TACC3 in JIMT-1 cells. BO-264 (25 mg/kg) reduces tumor volume and increases median survival in an EMT6 mouse xenograft model.

Reference

1. Akbulut, O., Lengerli, D., Saatci, O., *et al.* A highly potent TACC3 inhibitor as a novel anticancer drug candidate. *Mol. Cancer Ther.* **19(6)**, 1243-1254 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM